Viking Therapeutics, Inc. (VKTX) declined 1.74% to $32.13, underperforming the S&P 500's 0.59% loss. The company's upcoming EPS is projected at -$1, a 23.46% drop from the previous year. Analysts expect -$4.47 per share and $0 million in revenue for the fiscal year, a -40.13% and 0% change from the previous year, respectively. The Zacks Rank is #3 (Hold).

Viking Therapeutics

Viking Therapeutics Slumps 1.74% Amid Market Decline

Viking Therapeutics' 15-minute chart has exhibited a narrowing of Bollinger Bands, accompanied by a KDJ Death Cross at 09/10/2026 14:00. This indicates a diminution in the magnitude of stock price fluctuations, coupled with a shift in momentum towards the downside, which may potentially lead to further decreases in the stock price.Viking Therapeutics, Inc. (VKTX) has shown signs of bearish momentum in recent technical analysis, with its 15-minute chart indicating a narrowing of Bollinger Bands. This pattern suggests a reduction in price volatility and may signal a potential continuation of downward movement. At 14:00 on September 10, 2026, the stock also experienced <a href="https://www.google.com/goto?url=CAESpAEB6zswFSQnwB6rXtYFdBEj05SwnsHrFf8t13WCMV3oX2o6thdKPiwnvKeevAaFa7SMYXNzzirrML2KDW3aHyIJB6lQyBh1N8NbIrKbqalFujajlWlP-RlobqyrkaJud7TgCUML-ptlA5ydCyjJf1SOv2l_1ANrrn9kGu0WDkK_msbfvv0OjkJjQgziw97Kvq5QRJdM9u2GqTr-_j5RH53bGNPp1g">a KDJ Death Cross</a>, reinforcing the likelihood of a shift in momentum toward the downside.Technical indicators consistently show the stock trading below its 5, 20, 50, and 200-day exponential moving averages, confirming <a href="https://www.google.com/goto?url=CAESeAHrOzAVX7uPb6KsSqfH8IQJ3x_GY23jwivcJ2NTv823KWVAVP7DrGrhFI3LOUCQTItmTO3dBLHTnTMC5h441OB1FpcUrCf9AZT8l-UW4IDneQEfCHak8WjDtH7CrieFzH00jMqPuKzOey1Kv7u1QztBHxbEIYCizw">a strongly bearish trend</a> and ongoing selling pressure. The Bollinger Bands (25) currently range between 32.99 and 34.51, while the 100-period bands span 30.36 to 36.52, both <a href="https://www.google.com/goto?url=CAESeAHrOzAVX7uPb6KsSqfH8IQJ3x_GY23jwivcJ2NTv823KWVAVP7DrGrhFI3LOUCQTItmTO3dBLHTnTMC5h441OB1FpcUrCf9AZT8l-UW4IDneQEfCHak8WjDtH7CrieFzH00jMqPuKzOey1Kv7u1QztBHxbEIYCizw">suggesting a sell signal</a>. Additionally, the Relative Strength Index (RSI) stands at 44.37, indicating the stock is oversold, and the MACD (12, 26) is at -0.24, further <a href="https://www.google.com/goto?url=CAESeAHrOzAVX7uPb6KsSqfH8IQJ3x_GY23jwivcJ2NTv823KWVAVP7DrGrhFI3LOUCQTItmTO3dBLHTnTMC5h441OB1FpcUrCf9AZT8l-UW4IDneQEfCHak8WjDtH7CrieFzH00jMqPuKzOey1Kv7u1QztBHxbEIYCizw">supporting a bearish outlook</a>.Fundamentally, Viking Therapeutics is expected to report earnings that fall short of estimates in the coming quarters, with analysts forecasting <a href="https://www.google.com/goto?url=CAESbwHrOzAVCoklDzvlT2eO41CWSHqEcj4QFFOqZmWSAp5RamLDUKc5aWpHP_210TAdmxdPypR6AQ1tnPmveXySTuE0kzjGf_eApmb1tyOitoHrMkVZMSP49BWIofzemxpeTVWK486wQBYlmJQI43KA1A">a decline in earnings per share</a>. The stock’s current price of $32.70 is below its 52-week high of $43.15 and above its 52-week low of $22.96, reflecting <a href="https://www.google.com/goto?url=CAESeAHrOzAVX7uPb6KsSqfH8IQJ3x_GY23jwivcJ2NTv823KWVAVP7DrGrhFI3LOUCQTItmTO3dBLHTnTMC5h441OB1FpcUrCf9AZT8l-UW4IDneQEfCHak8WjDtH7CrieFzH00jMqPuKzOey1Kv7u1QztBHxbEIYCizw">a volatile but generally downward trajectory</a>. Investors should remain cautious as technical indicators and recent price action suggest a continuation of the bearish trend.

VikingTherapeutics

Viking Therapeutics' 15min chart shows Bollinger Bands Narrowing, KDJ Death Cross.

Axsome Therapeutics and Viking Therapeutics are two healthcare stocks under scrutiny for investment in 2026. Axsome focuses on commercializing treatments for depression and sleep disorders, with significant revenue growth and a settlement granting license rights for its Sunosi treatment. Viking Therapeutics targets the obesity market but has no products on the market yet. Both represent different stages of growth within biotech, making them popular choices for healthcare-minded portfolios.

Axsome Therapeutics

Axsome, Viking Therapeutics: Biotech Stocks Weighed Amid Growth, Obesity Targeting

Based on the 15-minute chart for nvTv Therapeutics, the Bollinger Bands are currently expanding downward and there has been a KDJ Death Cross at 09/10/2026 12:15. This suggests that the market trend is being driven by sellers and there is a significant momentum shift towards the downside, which could potentially lead to further decreases in the stock price.On September 10, 2026, the 15-minute chart for Viking Therapeutics, Inc. (VKTX) indicates a bearish shift in market dynamics. Bollinger Bands are currently expanding downward, signaling increased volatility and a potential continuation of the downward trend. Additionally, a KDJ Death Cross was observed at 12:15 PM, further reinforcing <a href="https://www.google.com/goto?url=CAEScgHrOzAVRnEZ-VJp9X8Ek5Jfmh2gFtePt5SZhmTrjhZXaqjcItmhs8LrxFGpwmzfCdwD3_YCFj24y3NdNHe6YLQSfnu94tfDzEvD9JWKkheldKEWvSJbJPM0k-Dwp5q-Oqvv_1bvTW1_oOyJaCYOgSV1NA">selling pressure and momentum shift</a>.Technical indicators suggest that the stock is trading below both its 5-day and 20-day moving averages, which are at <a href="https://www.google.com/goto?url=CAEScgHrOzAVRnEZ-VJp9X8Ek5Jfmh2gFtePt5SZhmTrjhZXaqjcItmhs8LrxFGpwmzfCdwD3_YCFj24y3NdNHe6YLQSfnu94tfDzEvD9JWKkheldKEWvSJbJPM0k-Dwp5q-Oqvv_1bvTW1_oOyJaCYOgSV1NA">33.76 and 33.82, respectively</a>. This positioning typically signals a weak market condition and may indicate that the stock is vulnerable to further declines. The daily support level is currently at 34.22, while resistance is at 35.61, with <a href="https://www.google.com/goto?url=CAEScgHrOzAVRnEZ-VJp9X8Ek5Jfmh2gFtePt5SZhmTrjhZXaqjcItmhs8LrxFGpwmzfCdwD3_YCFj24y3NdNHe6YLQSfnu94tfDzEvD9JWKkheldKEWvSJbJPM0k-Dwp5q-Oqvv_1bvTW1_oOyJaCYOgSV1NA">the price currently below support</a>.Historically, the Bollinger Bands for VKTX have shown a widening pattern, with the price hovering near the upper band in recent sessions. However, the recent downward expansion suggests <a href="https://www.google.com/goto?url=CAEScgHrOzAVRnEZ-VJp9X8Ek5Jfmh2gFtePt5SZhmTrjhZXaqjcItmhs8LrxFGpwmzfCdwD3_YCFj24y3NdNHe6YLQSfnu94tfDzEvD9JWKkheldKEWvSJbJPM0k-Dwp5q-Oqvv_1bvTW1_oOyJaCYOgSV1NA">a reversal in trend</a>. The KDJ Death Cross, a technical pattern where the short-term moving average crosses below the long-term moving average, is often interpreted as <a href="https://www.google.com/goto?url=CAESawHrOzAVxluhQHbDxXOlhKSoPeTfXybI4S6BKZmbqlrRJ5RauSz6995m_eXpPEnDRL7QDriRSGLzOUhw1wScpzBo7bYjXafOK2sgTgGdPIftf93IrH524GePm0DYzKjC_MAW-Cnpv8MFCcqC">a signal for continued downward movement</a>.While these indicators suggest a bearish outlook, it is important to note that technical analysis should be used in conjunction with other forms of market evaluation. Investors are advised to monitor key support and resistance levels and consider broader market conditions before making trading decisions.

vTv Therapeutics

vTv Therapeutics's 15min chart shows Bollinger Bands expanding downward, KDJ death cross.

Viking Therapeutics has a $92 target set by analysts, trading at $33. The biotech company is investigating its weight loss drug candidate in a phase 3 trial and preparing to launch another trial. Earlier trial results have been positive, making Viking a potential rival to pharma giants Eli Lilly and Novo Nordisk. Demand for GLP-1 drugs is high, supporting additional participants in the space. Lilly and Novo Nordisk's drugs were on the FDA drug shortage list due to high demand, and Viking is positioned to capitalize on this trend.

Eli Lilly

Novo Nordisk

Viking Therapeutics Faces High Bar to Reach $92 Target Amid GLP-1 Market Growth

Catalyst<ul> <li>Analyst ratings for VKTX include one Buy and one Strong Buy recommendation, indicating broad institutional optimism.</li></ul>Risk<ul> <li>Recent technical signals for VKTX are dominated by bearish indicators, with three bearish signals recorded against zero bullish ones.</li></ul>

Key Factors

VKTX shares fell 2.91% to close at $32.70, underperforming the S&P 500 and Nasdaq during the trading session.

VKTX News